Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On August 5, 2021 reported $33.1M cash, sufficient to fund completion of ongoing and upcoming clinical trials for drug candidate seclidemstat involving several types of solid and liquid cancers!!!!!!!!
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Actual Study Start Date : June 4, 2018
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : December 2021
https://clinicaltrials.gov/ct2/show/NCT03600649
Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma.
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.11514
Institutional Shares 10,171,876 - 22.72%
https://fintel.io/so/us/slrx
Salarius Pharmaceuticals (SLRX) - Probably One Of The Best Kept Secrets In The Biotech Space. This Is A Potential Multi-Bagger
remember: https://seekingalpha.com/instablog/50857529-johnsoriaknows/5622457-salarius-pharmaceuticals-slrx-probably-one-of-best-kept-secrets-in-biotech-space-this-is
Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index
The FTSE Global Equity Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies
https://www.globenewswire.com/news-release/2021/09/20/2299689/0/en/Salarius-Pharmaceuticals-Added-to-FTSE-Global-Micro-Cap-Index.html
Bought a starter block here Friday
Looks like a nefarious loan structure as indicated by the volume and reversal. Most likely includes warrants as well. Made monies on the channeling and last stretch run.
Took a stake and pulled out on earnings release. Factor in current market conditions, and geo political climate, best to go sidelined until the turbulence is over.
This has been incredible the past few days!!! And I feel like we are still under the radar.
Someone is loading, pay attention here!
800k volume on a 5 minute candle and a 10% spike. Someone is loading!!
Heating up again
Bought 1.40, aktivasion
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement https://seekingalpha.com
Yes a Form 4 showing Stock Option -right to buy at .74 for 30k shares Dec 2021
I only see form 4s from Aug nothing current. Doubt they could buy since they were selling the warrants at a discount to original price $1.15 drop to .90
So it appears most of the chief executives have all filed form 4's over the past 30 days, acquiring additional shares. They obviously know something is about to pop! I think this past week's jump is just the beginning.
I'm on board giving it a chance due to insider buying.
Salarius Pharmaceuticals to Present During Virtual LD 500 Conference https://seekingalpha.com
That was quick.
Salarius Announces Closing of $6.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option https://seekingalpha.com
SLRX to expand clinical trials to additional sarcomas.
https://www.globenewswire.com/news-release/2020/07/29/2069783/0/en/Salarius-Pharmaceuticals-to-Expand-Clinical-Program-to-Target-Additional-Sarcomas-in-Ewing-Sarcoma-Phase-1-2-Clinical-Trial.html
SLRX moves corporate office to Texas medical center and opens new laboratory to J&J’s JLAB!! Lots of changes happening here!
Salarius Pharmaceuticals Announces Move to New Corporate Offices at Texas Medical Center https://seekingalpha.com
Salarius Pharmaceuticals Names Nadeem Mirza, M.D., M.P.H., as Senior Vice President Clinical Development https://seekingalpha.com
Chart is looking good now. Daily volume has double in the last 10 minutes.
$1.65 is huge resistance mark for SLRX. Now broken with green hammer. Let’s see if we get bullish here now!
1.25 off of 1.70 hi after halt resume
SLRX
Salarius Pharmaceuticals to Present Trial in Progress Poster at ASCO20 Virtual Scientific Program https://seekingalpha.com
Nice. Good for you.
I have no idea. Only thing recent is that they didn’t lose as much money as expected on their quarterly. Which is what the merger and shake up was planned to do, tighten the reigns and set new management, etc. Plan is in motion I guess.
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
177
|
Created
|
08/12/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |